Careseng 1370 for Chemotherapy-Induced Myelosuppression

Summary

This is a Phase I/IIa dose-finding (Phase I) followed by randomized, double-blind, placebo-controlled, parallel, add-on to cisplatin + docetaxel (Phase IIa) study to evaluate the safety, tolerability, and efficacy profiles of Careseng 1370 in subjects with advanced NSCLC.

Timeline

Start

2019-03

Primary completion

2021-03

Completion

2021-06

Outcome

Outcome not reported

Stopped: “At sponsor's discretion”

Drugs

Indications